We are proud to announce that PhenoPath is now a Quest Diagnostics Company.

Company News

Lung Fluid Versus Tissue Biopsy for Mesothelioma Diagnosis

New Mesothelioma Study Compares Lung Fluid and Biopsy for Diagnosis, According to Surviving Mesothelioma

The pathologists from PhenoPath and the University of British Columbia found that certain genetic alterations were seen just as often in the fluid samples of mesothelioma patients as they were in tissue samples.

“We conclude that both BAP1 immunohistochemistry and p16 FISH analysis provide reliable markers of mesothelial malignancy [mesothelioma] in effusion cytology specimens.” writes lead researcher Harry Hwang, MD of PhenoPath.

Scientists in Seattle and Vancouver compared the diagnostic value of lung fluid cytology (effusion cytology) versus tissue biopsy in 18 patients with or without mesothelioma.  Surviving Mesothelioma has just posted an article on the new research. 

Click here to read it now.